Over the past year there were no insider purchases at Bright Minds Biosciences Inc.. One insider sold roughly $9.8 million instead.
Keep in mind most insider selling is routine — stock-based pay has to be converted to cash at some point.
Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters. Big money check: 100 institutions held DRUG as of Q2 2026, and more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | Cormorant Asset Management, LP | Other | Sell | 109,331 | $89.50 | $9.8M | SEC |
| Nov 6, 2024 | Cormorant Asset Management, LP | 10% Owner | Buy | 184,331 | $21.70 | $4.0M | SEC |
| Oct 17, 2024 | Cormorant Global Healthcare Master Fund, LP | 10% Owner | Buy | 2,600 | $8.80 | $23K | SEC |
| Oct 17, 2024 | Cormorant Global Healthcare Master Fund, LP | 10% Owner | Buy | 7,150 | $24.03 | $172K | SEC |
| Oct 17, 2024 | Cormorant Global Healthcare Master Fund, LP | 10% Owner | Buy | 238,097 | $4.53 | $1.1M | SEC |
| Oct 17, 2024 | Cormorant Global Healthcare Master Fund, LP | 10% Owner | Buy | 63,173 | $5.92 | $374K | SEC |
| Oct 17, 2024 | Cormorant Global Healthcare Master Fund, LP | 10% Owner | Buy | 33,343 | $6.42 | $214K | SEC |
| Oct 17, 2024 | Cormorant Global Healthcare Master Fund, LP | 10% Owner | Buy | 8,900 | $7.31 | $65K | SEC |
| Oct 17, 2024 | Cormorant Global Healthcare Master Fund, LP | 10% Owner | Buy | 3,107 | $25.22 | $78K | SEC |
| Oct 17, 2024 | Cormorant Global Healthcare Master Fund, LP | 10% Owner | Buy | 2,700 | $9.26 | $25K | SEC |
| Oct 17, 2024 | Cormorant Global Healthcare Master Fund, LP | 10% Owner | Buy | 19,169 | $11.72 | $225K | SEC |
| Oct 17, 2024 | Cormorant Global Healthcare Master Fund, LP | 10% Owner | Buy | 4,609 | $12.35 | $57K | SEC |
| Oct 17, 2024 | Cormorant Global Healthcare Master Fund, LP | 10% Owner | Buy | 39,743 | $23.22 | $923K | SEC |
In the last 12 months Bright Minds Biosciences Inc. insiders made open-market purchases worth about $0 and sales worth about $9.8 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in DRUG was filed on 2026-04-30.
100 investment managers reported holding DRUG in SEC Form 13F filings for Q2 2026.
No congressional trades in DRUG were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).